NASDAQ$ROIV
Roivant Sciences Ltd · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Roivant Sciences reported its financial results and provided a business update.
Roivant Sciences reported its financial results for the third fiscal quarter ended December 31, 2021. The company had cash and cash equivalents of approximately $2.2 billion as of December 31, 2021. R&D expenses were $153.5 million, and G&A expenses were $115.5 million. Net loss for the quarter was $306.1 million.
- Hemavant entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to RVT-2001.
- Dermavant hired key commercial leadership positions in preparation for launch of tapinarof for psoriasis.
- Immunovant achieved alignment with the FDA for a pivotal Phase 3 study of batoclimab in myasthenia gravis.
- The FDA cleared the IND submitted by Kinevant for a Phase 2 trial evaluating namilumab for the treatment of sarcoidosis.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$17.1M
Forward guidance
Roivant anticipates several major milestones.
Tailwinds
- Dermavant expects a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second quarter of calendar year 2022.
- Dermavant expects to report topline data from the Phase 3 clinical trial of tapinarof for the treatment of atopic dermatitis in the first half of calendar year 2023.
- Immunovant plans to initiate a pivotal trial evaluating batoclimab for the treatment of myasthenia gravis in 1H 2022, with topline results expected in 2024.
- Immunovant also plans to re-initiate its programs in thyroid eye disease and warm autoimmune hemolytic anemia in 2022, and to announce at least two new indications by August 2022.
- Aruvant expects to announce ongoing new patient and follow up data through 2022 and to initiate its Phase 3 trial for ARU-1801 for the treatment of sickle cell disease in 2023.
Headwinds
- The company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.
- Actual results may differ materially from those described in the forward-looking statements.
- All product candidates referenced in this press release are investigational and subject to health authority approval.
- The company's future performance is subject to risks, uncertainties and assumptions.
- The company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro